Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 14/20 | 0.58 |
| ▸ | DYRK2 | Q92630 | 13/20 | 0.58 |
| ▸ | DYRK1B | Q9Y463 | 12/20 | 0.58 |
| ▸ | DYRK3 | O43781 | 11/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 9/20 | 0.58 |
| ▸ | CDK5R1 | Q15078 | 9/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.58 |
| ▸ | CDK2 | P24941 | 8/20 | 0.58 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.58 |
| ▸ | CDK9 | P50750 | 8/20 | 0.58 |
| ▸ | FYN | P06241 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13234221 | 0.81 | FYN (0.68) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL3513641 | 0.80 | FYN (0.74) | FYN | |
| SCHEMBL13234222 | 0.80 | DYRK1A (0.58) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL13234228 | 0.79 | DYRK1A (0.69) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL3043884 | 0.78 | FYN (0.67) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL13234223 | 0.77 | FYN (0.61) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL477064 | 0.77 | DYRK1A (0.70) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL477039 | 0.77 | PRMT5 (0.45) | DYRK1A | |
| SCHEMBL16216115 | 0.77 | DYRK1A (0.74) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL3029524 | 0.76 | GABRA1 (0.48) | DYRK1AFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| EP-2176266-A2 | SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES AS KINASE INHIBITORS, THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| WO-2007025540-A2 | SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES AS KINASE INHIBITORS, THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007025540-A2 | SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES AS KINASE INHIBITORS, THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | DYRK1A 461/4885DYRK2 336/4885DYRK1B 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.